EXHIBIT 10.2 CONFIDENTIAL TREATMENT DEVELOPMENT AND MANUFACTURING AGREEMENT This development and manufacturing agreement is made and entered into on this 12th day of July 2000.Development and Manufacturing Agreement • November 14th, 2000 • Cytogen Corp • In vitro & in vivo diagnostic substances • England
DEVELOPMENT AND MANUFACTURING AGREEMENTDevelopment and Manufacturing Agreement • November 21st, 2014 • Viveve Medical, Inc. • Electromedical & electrotherapeutic apparatus • California
This Development and Manufacturing Agreement (the "Agreement") is made and entered into as of 12 day of June 2006 (the "Effective Date") by and between Stellartech Research Corporation ("Stellartech"), a California corporation with a principal place of business at 1346 Bordeaux Drive, Sunnyvale, CA 94089, and TiVaMed, Inc. ("Company"), a Delaware Corporation with a principal place of business at 900 Welch Road, Palo Alto, California 94304 (each referred to below as a "party" or collectively as the "parties").
DEVELOPMENT AND MANUFACTURING AGREEMENT FOR RGB-LASERSDevelopment and Manufacturing Agreement • June 10th, 1997 • Laser Power Corp/Fa • Optical instruments & lenses • California
AMENDMENT NO. 1 TO DEVELOPMENT AND MANUFACTURING AGREEMENTDevelopment and Manufacturing Agreement • June 22nd, 2009 • Cornerstone Therapeutics Inc • Pharmaceutical preparations • New York
This Amendment No. 1 to Development and Manufacturing Agreement (this “Amendment”) is dated June 16, 2009 (the “Amendment Date”), by and between Cornerstone BioPharma, Inc. a Nevada corporation with its principal offices located at 1255 Crescent Green Drive, Suite 250, Cary, NC 27518 (“Company”), NEOS Therapeutics, L.P., a Texas limited partnership (“Manufacturer”) with its principal offices located at 2940 N. Hwy. 360, Suite 100, Grand Prairie, TX 75050 and Coating Place, Inc., a Wisconsin corporation (“Supplier”) with its principal offices located at 200 Paoli Street, P.O. Box 930310, Verona, WI, 53593. Manufacturer, Supplier and Company sometimes are referred to herein individually as a “Party” and collectively as the “Parties.”
DEVELOPMENT and MANUFACTURING AGREEMENT This Agreement is made and entered into this 15th day of August, 2007, by and between Startale Group Inc., a Nevada corporation, having its principal office at 4320 Winfield Road, Suite 200 Warrenville, Illinois...Development and Manufacturing Agreement • October 2nd, 2007 • Startale Group Inc. • Nevada
THIRD AMENDED AND RESTATED DEVELOPMENT AND MANUFACTURING AGREEMENTDevelopment and Manufacturing Agreement • February 2nd, 2012 • Plantronics Inc /Ca/ • Telephone & telegraph apparatus • California
This THIRD AMENDED AND RESTATED Development Manufacturing Agreement (this "Agreement") is made and entered into as of October 15, 2011 (the “Effective Date”) between: PLANTRONICS B.V., a Netherlands corporation, with principal offices at Southpoint, Building C, Scorpius 140, 2132 LR Hoofddorp, the Netherlands ("Plantronics") and, for certain limited purposes as set forth herein Plantronics Communications Technology (Suzhou) Co. Ltd. (“Plantronics PCH”), and GoerTek, Inc. , a Chinese business entity , acting on behalf of itself and its Affiliates, with its principal place of business located at No. 268 Dong Fank Road; Hi Tech Industry Development District; Wei Fang, Shandong 266031. (“GoerTek ”).
ContractDevelopment and Manufacturing Agreement • August 15th, 2008 • Neurologix Inc/De • Pharmaceutical preparations
DEVELOPMENT AND MANUFACTURING AGREEMENTDevelopment and Manufacturing Agreement • May 13th, 2005 • Neurologix Inc/De • Pharmaceutical preparations • Minnesota
THIS DEVELOPMENT AND MANUFACTURING AGREEMENT (this "Agreement") is made and entered into as of April 27, 2005 ("Effective Date"), by and among Neurologix, Inc., a Delaware corporation and Neurologix Research, Inc., a Delaware corporation (collectively "Neurologix") and Medtronic, Inc., a Minnesota corporation ("Medtronic"). Each of the above is sometimes referred to herein individually as a "Party" and collectively as the "Parties."
FIRST AMENDMENT TO GPEx® DEVELOPMENT AND MANUFACTURING AGREEMENTDevelopment and Manufacturing Agreement • November 1st, 2018 • DiaMedica Therapeutics Inc. • Pharmaceutical preparations
This First Amendment to GPEx® Development and Manufacturing Agreement (this “Amendment”), is made as of this 10th day of April, 2017 (“Amendment Effective Date”), by and between DiaMedica Therapeutics Inc., a Manitoba corporation, with a place of business at Two Carlson Parkway, Suite 165, Minneapolis, MN 55447 (“Client”), and Catalent Pharma Solutions, LLC, a Delaware limited liability company, with a place of business at 14 Schoolhouse Road, Somerset, NJ 08873, USA (“Catalent”).
Development and Manufacturing AgreementDevelopment and Manufacturing Agreement • November 6th, 2017 • Hancock Jaffe Laboratories, Inc. • Surgical & medical instruments & apparatus
This Development and Manufacturing Agreement (the “Agreement”) is made and entered into on this 1st day of February, 2013, by and between Hancock Jaffe Laboratories Aesthetics, Inc. (“HJLA”), a Delaware corporation having a business address at 70 Doppler, Irvine, California and Hancock Jaffe Laboratories, Inc. (the “Company”), a Delaware corporation.
PROCESS DEVELOPMENT AND MANUFACTURING AGREEMENTDevelopment and Manufacturing Agreement • September 24th, 2009 • Prana Biotechnology LTD • Pharmaceutical preparations • England
This PROCESS DEVELOPMENT AND MANUFACTURING AGREEMENT (hereinafter “Agreement”) is made by and between Prana Biotechnology Ltd ACN 080 699 065 (“Prana”), a company incorporated in Australia whose registered office and principal place of business is at Level 2,369 Royal Parade, Parkville Victoria 3052 and Dr. Reddy’s Laboratories Limited (“Dr. Reddy’s”), a company incorporated and existing under the laws of India, having its principal place of business at 7-1-27 Ameerpet Hyderabad 500 016 India.
DEVELOPMENT AND MANUFACTURING AGREEMENTDevelopment and Manufacturing Agreement • September 9th, 2004 • Dragon Pharmaceuticals Inc • Pharmaceutical preparations
Dragon Pharmaceutical, Inc., a corporation duly incorporated under the laws of the state of Florida, USA, having an office at 1900-1055 West Hastings St., Vancouver, British Colombia, Canada, and duly licensed to do business there.
SECOND AMENDMENT TO DEVELOPMENT AND MANUFACTURING AGREEMENTDevelopment and Manufacturing Agreement • November 10th, 2015 • Surgiquest Inc • Surgical & medical instruments & apparatus
This Second Amendment to Development and Manufacturing Agreement (this “First Amendment”) is made as of December 15th, 2014 (“Second Amendment Effective Date”) by and among W.O.M. World of Medicine, GmbH, a German corporation with a place of business at Salzufer 8, 10587 Berlin (“WOM Germany”), W.O.M. World of Medicine, USA, a Florida corporation with a place of business at 4531 36th St., Orlando, FL 32801 (“WOM USA,” and together with WOM Germany, “WOM”) and SurgiQuest, Inc., a Delaware corporation with its principal place of business at 333 Quarry Road Milford, CT 06460 (“SurgiQuest”).
SECOND AMENDED AND RESTATED DEVELOPMENT AND MANUFACTURING AGREEMENT Between PLANTRONICS B.V. and GOERTEK, INC. *** Certain information in this Agreement has been omitted and filed separately with the Securities and Exchange Commission. Confidential...Development and Manufacturing Agreement • May 26th, 2009 • Plantronics Inc /Ca/ • Telephone & telegraph apparatus • California
This SECOND AMENDED AND RESTATED DEVELOPMENT MANUFACTURING AGREEMENT (this "Agreement") is made and entered into as of March 20, 2009 (the “Effective Date”) between: PLANTRONICS B.V., a Netherlands corporation, with principal offices at Southpoint, Building C, Scorpius 140, 2132 LR Hoofddorp, the Netherlands ("Plantronics") and, for certain limited purposes as set forth herein Plantronics Communications Technology (Suzhou) Co. Ltd. (“Plantronics PCH”), and GoerTek, Inc. , a Chinese business entity , acting on behalf of itself and its Affiliates, with its principal place of business located at No. 268 Dong Fank Road; Hi Tech Industry Development District; Wei Fang, Shandong 266031. (“GoerTek ”).
FIRST AMENDMENT TO GPEx® DEVELOPMENT AND MANUFACTURING AGREEMENTDevelopment and Manufacturing Agreement • October 19th, 2018 • DiaMedica Therapeutics Inc. • Pharmaceutical preparations
This First Amendment to GPEx® Development and Manufacturing Agreement (this “Amendment”), is made as of this 10th day of April, 2017 (“Amendment Effective Date”), by and between DiaMedica Therapeutics Inc., a Manitoba corporation, with a place of business at Two Carlson Parkway, Suite 165, Minneapolis, MN 55447 (“Client”), and Catalent Pharma Solutions, LLC, a Delaware limited liability company, with a place of business at 14 Schoolhouse Road, Somerset, NJ 08873, USA (“Catalent”).
ImmuCell CorporationDevelopment and Manufacturing Agreement • August 16th, 2010 • Immucell Corp /De/ • In vitro & in vivo diagnostic substances • Delaware
Confidential Treatment as to certain portions has been requested, which portions have been omitted and filed separately with the Securities and Exchange Commission
DEVELOPMENT AND MANUFACTURING AGREEMENT THIS AGREEMENT is made on the day of 2005 (Effective Date) BETWEENDevelopment and Manufacturing Agreement • October 13th, 2005 • Capacitive Deionization Technology Systems Inc • Water supply • Texas
AMENDMENT #1 TO THEDevelopment and Manufacturing Agreement • August 13th, 2002 • Onyx Pharmaceuticals Inc • Biological products, (no disgnostic substances)
This Amendment #1 to the Process Development and Manufacturing Agreement (the “Amendment”) is made and entered into on April 15, 2002 by and between ONYX Pharmaceuticals, Inc., a Delaware Corporation having its principal place of business at 3031 Research Drive, Richmond, California 94806 (“ONYX”), and XOMA (US) LLC, a Delaware limited liability company (“XOMA”) with offices at 2910 Seventh Street, Berkeley, California 94710. ONYX and XOMA are sometimes referred to herein individually as a “Party” and collectively as “Parties.”
SECOND AMENDMENT TO GPEx® DEVELOPMENT AND MANUFACTURING AGREEMENTDevelopment and Manufacturing Agreement • March 23rd, 2020 • DiaMedica Therapeutics Inc. • Pharmaceutical preparations
This Second Amendment to GPEx® Development and Manufacturing Agreement (this “Amendment”), is made as of this 22nd day of October, 2018 (“Amendment Effective Date”), by and between DiaMedica Therapeutics, Inc., a Manitoba corporation, with a place of business at 2 Carlson Parkway, Suite 260 Minneapolis, MN 55447 (“Client”), and Catalent Pharma Solutions, LLC, a Delaware limited liability company, with a place of business at 14 Schoolhouse Road, Somerset, NJ 08873, USA (“Catalent”).
DEVELOPMENT AND MANUFACTURING AGREEMENTDevelopment and Manufacturing Agreement • November 30th, 2012 • AVRA Surgical Robotics, Inc. • Blank checks
This Development and Manufacturing Agreement (“Agreement”) is made and entered into as of the ___ day of October, 2012, by and between MIS-Robotics GmbH, a German corporation with offices at Am Technologiepark 12, 82229 Seefeld, HRB 200457 Amtsgericht München (“MIS”), and RG Mechatronics GmbH, a German corporation with offices at Am Technologiepark 12, 82229 Seefeld, HRB 172994 Amtsgericht München (“RGM”).
DEVELOPMENT AND MANUFACTURING AGREEMENTDevelopment and Manufacturing Agreement • September 29th, 2003 • Palatin Technologies Inc • Pharmaceutical preparations
BY AND BETWEEN: Palatin Technologies, Inc., a Delaware corporation, having an address of 4-C Cedar Brook Drive, Cedar Brook Corporate Center, Cranbury, NJ 08512 (hereinafter referred to as "Palatin");
THIRD AMENDMENT TO DEVELOPMENT AND MANUFACTURING AGREEMENTDevelopment and Manufacturing Agreement • May 14th, 2008 • Icop Digital, Inc • Radio & tv broadcasting & communications equipment
THIS THIRD AMENDMENT TO DEVELOPMENT AND MANUFACTURING AGREEMENT is made this 26th day of March, 2008, by and among ICOP DIGITAL, INC., a Colorado Corporation, (“ICOP DIGITAL”) and the TIETECH CO., LTD., a Japanese Corporation, (“TIETECH”).
DEVELOPMENT AND MANUFACTURING AGREEMENTDevelopment and Manufacturing Agreement • November 5th, 2008 • Cornerstone Therapeutics Inc • Pharmaceutical preparations • New York
THIS DEVELOPMENT AND MANUFACTURING AGREEMENT (this “Agreement”) is made effective the 27th day of February, 2008, among Cornerstone BioPharma, Inc., a Delaware corporation (“Company”), NEOS Therapeutics, L.P., a Texas limited partnership (“Manufacturer”) and Coating Place, Inc., a Wisconsin corporation (“Supplier”). Manufacturer, Supplier, and Company are sometimes referred to herein individually as a “Party” and collectively as the “Parties.”
CONFIDENTIAL MATERIAL OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION. DEVELOPMENT AND MANUFACTURING AGREEMENTDevelopment and Manufacturing Agreement • March 20th, 2009 • Icop Digital, Inc • Radio & tv broadcasting & communications equipment • Kansas
This Development and Manufacturing Agreement (“Agreement”) dated November 5, 2008, is entered into by ICOP DIGITAL, INC., a corporation organized and existing under the laws of the State of Kansas with its principal place of business located at 16801 West 116th Street, Lenexa, KS 66219, USA (“ICOP DIGITAL”), and EVERFOCUS ELECTRONICS CORPORATION, a corporation organized and existing under the laws of Taiwan with its principal business address at 12F, No. 79, Sec. 1, Shin-Tai Wu Road, Hsi-Chi, Taipei Hsien, Taiwan, R.O.C.; and at 1801 Highland Ave. Unit A, Duarte, CA 91010 USA (“EVERFOCUS”) and, each of whom is individually referred to as a “Party” and both of whom are sometimes collectively referred to as “Parties.”
Development and Manufacturing AgreementDevelopment and Manufacturing Agreement • September 11th, 2007 • B2 Health, Inc. • Colorado
This development and manufacturing Agreement is entered into as of February 20, 2007 by and between Technology Driven Products, Inc., a Colorado corporation (“TDP”) and Back 2 Health Ltd., a Colorado corporation (“Back 2 Health”).
DEVELOPMENT AND MANUFACTURING AGREEMENTDevelopment and Manufacturing Agreement • November 10th, 2015 • Surgiquest Inc • Surgical & medical instruments & apparatus • Connecticut
This Development and Manufacturing Agreement (this “Agreement”) is made as of October 12, 2009 (the “Effective Date”) by and among SurgiQuest, Inc., a Delaware corporation having a place of business at 12 Cascade Boulevard, Orange, Connecticut 06477 (“SurgiQuest”), W.O.M. WORLD OF MEDICINE AG, a German corporation having a place of business at Salzufer 8 in 10587 Berlin (“WOM Germany”), and W.O.M. WORLD OF MEDICINE USA, Inc., a Florida corporation having a place of business at 4531 36th Street in Orlando, Florida 32801 (“WOM USA,” and collectively with WOM Germany, “WOM”). SurgiQuest and WOM may herein be referred to individually as a “Party” and collectively as the “Parties.”
PRODUCT DEVELOPMENT and MANUFACTURING AGREEMENTDevelopment and Manufacturing Agreement • May 23rd, 2023 • CardieX LTD • Electromedical & electrotherapeutic apparatus • Hong Kong
THIRD AMENDMENT TO GPEx® DEVELOPMENT AND MANUFACTURING AGREEMENTDevelopment and Manufacturing Agreement • March 19th, 2024 • DiaMedica Therapeutics Inc. • Pharmaceutical preparations
This Third Amendment to GPEx® Development and Manufacturing Agreement (this “Amendment”), is made as of this 11th day of April 2022 (“Amendment Effective Date”), by and between DiaMedica Therapeutics, Inc., a Manitoba corporation, with a place of business at 2 Carlson Parkway, Suite 260 Minneapolis, MN 55447 (“Client”), and Catalent Pharma Solutions, LLC, a Delaware limited liability company, with a place of business at 14 Schoolhouse Road, Somerset, NJ 08873, USA (“Catalent”).
